



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : <b>A61N 1/05</b></p>	<p><b>A1</b></p>	<p>(11) International Publication Number: <b>WO 99/65561</b></p> <p>(43) International Publication Date: 23 December 1999 (23.12.99)</p>
<p>(21) International Application Number: PCT/US99/13719</p> <p>(22) International Filing Date: 17 June 1999 (17.06.99)</p> <p>(30) Priority Data:  60/090,009 19 June 1998 (19.06.98) US  60/110,054 25 November 1998 (25.11.98) US</p> <p>(71) Applicant: CORDIS WEBSTER, INC. [US/US]; 3333 Diamond Canyon Road, Diamond Bar, CA 91765 (US).</p> <p>(71)(72) Applicants and Inventors: SCHERLAG, Benjamin, J. [US/US]; 11403 Spring Hollow Road #207, Oklahoma City, OK 73120 (US). SCHERLAG, Michael [US/US]; 7304 N.W. 111th Terrance, Oklahoma City, OK 73162 (US). SCHAURTE, Patrick [US/US]; Chevy Chase Apartments, 6490 N. Warren #279, Oklahoma City, OK 73116 (US).</p> <p>(72) Inventor: WEBSTER, Wilton, W., Jr.; 3333 Diamond Canyon Road, Diamond Bar, CA 91765 (US).</p> <p>(74) Agent: DILLARD, David, A.; Christie, Parker &amp; Hale, LLP, P.O. Box 7068, Pasadena, CA 91109-7068 (US).</p>		<p>(81) Designated States: CA, DE, FI, GB, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p><b>Published</b>  <i>With international search report.  Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: METHOD AND APPARATUS FOR TRANSVASCULAR TREATMENT OF TACHYCARDIA AND FIBRILLATION</p>		
<p>(57) Abstract</p> <p>The present invention provides a method of controlling cardiac fibrillation, tachycardia, or cardiac arrhythmia by the use of an electrophysiology catheter (10) having a tip section (12) that contains at least one stimulating electrode (14, 16), the electrode being stably placed at a selected intravascular location. The electrode is connected to a stimulating means (18). Stimulation is applied across the wall of the vessel, trans-vascularly, to a sympathetic or parasympathetic nerve that innervates the heart at a strength sufficient to depolarize the nerve, and effect the control of the heart.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

1 METHOD AND APPARATUS FOR TRANSVASCULAR TREATMENT OF  
TACHYCARDIA AND FIBRILLATION

BACKGROUND OF THE INVENTION

5 The field of the invention is the control of tachycardia, including fibrillation, and arrhythmias, particularly the control of atrial fibrillation and ventricular tachycardia.

Tachycardia is the rapid beating of the heart, caused by abnormalities in any part of the heart, for example the atria, Purkinje system, or ventricles. Often, the extremely rapid beating of the heart is uncoordinated, and leads to fibrillation or flutter. These conditions  
10 occur after myocardial infarctions, for example, or in various pathological conditions, such as a dilated heart, blockage of the Purkinje system, or following chemical therapies (e.g., epinephrine) or repetitive stimulation. Atrial flutter often becomes atrial fibrillation within a few days or weeks, and leads to a complete failure of the atria to pump blood.

Atrial fibrillation is the most frequent tachycardia in patients. It most frequently occurs  
15 in patients over the age of 60 years, and affects over 8% of patients with cardiovascular disease and people older than 80 years (1, 2). Chronic atrial fibrillation doubles mortality (3), mostly due to an increased risk of stroke as well as other cardiovascular complications. Among other risk factors, congestive heart disease imposes the highest risk for developing atrial fibrillation (4.5-5.9 fold) (4). Therefore, restoration of normal sinus rhythm by  
20 pharmacological or electrical cardioversion is attempted in many patients with atrial fibrillation. Unfortunately, atrial fibrillation recurrence rates one year after successful cardioversion are high (75% without antiarrhythmic drug prophylaxis and 50% with aggressive antiarrhythmic medication; (5)). Moreover, the likelihood of cardioversion success is low in patients with chronic atrial fibrillation lasting longer than 2 years or who have enlarged atria  
25 (6). In many of these patients, therapy is directed toward ventricular rate control during atrial fibrillation in order to stabilize cardiac function. However, in patients with concomitant heart failure, drugs that slow the ventricular rate during atrial fibrillation may further depress ventricular contractility and cause arterial hypotension or be of limited use due to side effects.

Like atrial fibrillation, ventricular tachycardia can lead to fibrillation, which leads to  
30 failure of the ventricles to pump blood. Unlike atrial fibrillation, ventricular fibrillation cannot be compensated for by the rest of the heart and rapidly leads to sudden death if not reversed. Ventricular fibrillation is a common cause of death in patients (7). For example, patients who survive myocardial infarction often remain at risk for reentrant ventricular tachycardia. The sympathetic and parasympathetic nerves (autonomic innervation) of the heart  
35 influence susceptibility to spontaneous arrhythmias. Sympathetic stimulation can increase the risk of fatal arrhythmias during ischemic events and parasympathetic stimulation can decrease the risk (8). Current efforts to control this excess sympathetic tone include administration of  $\beta$ -adrenergic blocking drugs and surgical sympathectomy (9). Problems with these methods

1 include contraindications for drug therapy in patients who are sensitive to the negative inotropic effects of  $\beta$ -adrenergic blockade and the inherent risks of thoracic surgery, which in this case also include pulmonary complications, injury to the brachial plexus, and upper extremity paresthesias.

5 Another common measure used to control atrial or ventricular tachycardia is ablation or modification of the His bundle or atrioventricular node and ablation of atrial or ventricular foci. Such ablation may abolish a tachycardia or slow the ventricular response during atrial fibrillation by blocking impulse conduction across the atrioventricular node. Ablation can be performed by introduction of a catheter into the heart through the venous system and subsequent ablation of  
10 the tissue.

In 1973, Lazzara and Scherlag reported that electrical stimulation of parasympathetic cardiac nerves at the junction of the right atrium and the inferior vena cava close to the coronary sinus ostium selectively prolonged atrio-ventricular (AV) conduction time (10). Chen *et al.* showed control of ventricular rate during atrial fibrillation by short bursts of stimulation to  
15 parasympathetic nerves in the fat pads to the AV node, but this method can lead to unwanted stimulation of myocardial muscle, and stimulation times are necessarily very brief because the electrode cannot be stably maintained in the appropriate location. Most recently, Reek *et al.* (12) reported that stimulation of the parasympathetic nerve fibers in the RPA with a conventional electrode catheter decreased the sinus rate in sheep. In addition, electrical stimulation of  
20 parasympathetic nerves either during coronary artery bypass grafting operation (CABG) (13) or after CABG operation (14) have demonstrated that parasympathetic fibers innervating the sinus and atrioventricular node can also be stimulated in humans. The stimulation electrodes, however, were only temporarily fixed at the outer surface of the heart or superior vena cava. Chiou *et al.* demonstrated that extracardiac electrical stimulation of parasympathetic fibers in fat  
25 pad between the superior vena cava, the aorta, and adjacent to the right pulmonary artery, diminished AV nodal conduction during sinus rhythm (15). These results required a thoracotomy. Most recently, Thompson and coworker reported that endovascular electrical stimulation of parasympathetic fibers in the superior vena cava with a conventional electrode catheter slows the sinus rate (16).  
30

#### SUMMARY OF THE INVENTION

The present invention provides a method and system for controlling the heart rate of a patient and is particularly useful in controlling cardiac fibrillation and tachycardia. The method  
35 involves the intravascular stimulation and/or ablation of cardiac parasympathetic and sympathetic nerves sufficient to regulate or slow the heart rate or prevent the occurrence of these arrhythmias.

The method comprises providing an electrophysiology catheter comprising at least one

1 electrode and preferably an electrode array, e.g., in an expandable electrode basket, at its distal  
end. The catheter is inserted into a blood vessel and directed to a location wherein the electrode  
through which a stimulus is delivered is adjacent to one or more predetermined cardiac  
parasympathetic or sympathetic nerves. A selected stimulus preferably a pulsed electrical signal,  
5 is then delivered through the electrode(s) to slow or regulate the beating rate of the heart. The  
stimulus is maintained for an extended period to provide a physician sufficient time to administer  
a drug, operate or take other appropriate measures to attempt to permanently or at least more  
permanently establish normal heart rhythm or slow the heart rate. Such a period may require  
several hours.

10 The selected stimulus is preferably below the threshold needed to depolarize the cardiac  
muscle or it is applied sufficiently far from the cardiac muscle so that depolarization does not  
occur. Alternatively, a stronger stimulus intensity may be used if it is timed to occur during  
the myocardial refractory period. The refractory period can be induced at regular intervals  
by pacing the contraction of the myocardium with electrical pulses applied from the same or  
15 a different electrode as is used to apply the nerve stimulation.

A preferred stimulus for stimulating a predetermined parasympathetic nerve is a pulsed  
electrical signal having a frequency of from about 1 to about 200 Hz, preferably about 20 -  
30 Hz, having an intensity or strength of from about 1 to about 200 volts as measured at the  
electrodes tissue interface, preferably from about 8 to about 15 volts. The duration of each  
20 stimulating pulse is from about 1 microsecond to about 10 milliseconds, preferably from about  
50  $\mu$ sec (0.05 ms) to about 600  $\mu$ sec (0.6 ms), most preferably from about 50  $\mu$ sec to about  
100  $\mu$ sec.

It is understood that the frequency, intensity and duration of the signal may vary. For  
example, depending on the precise location of the electrode through which a stimulus is  
25 delivered and the nerve to be stimulated, a signal of greater or lesser strength may be  
required. In such a situation, the stimulus can be varied during the procedure until the desired  
slowing of the heart rate is achieved. That is, if no response is achieved initially, the voltage  
may be increased in steps, e.g., of 5-10 volts/step until a response is seen. Likewise, the  
frequency, pulse duration and polarity may be adjusted. Clearly, other parameters may be  
30 varied including the location of the electrode to achieve and/or improve the response.

It is further understood that the stimulating signal may be of sufficient intensity,  
frequency and duration to ablate the nerve. This is done, for example, if a patient is at high  
risk of ventricular tachycardia from cardiac sympathetic stimulation, common after myocardial  
infarction, where the patient has vagally maintained atrial fibrillation (17). Stimulation  
35 frequencies in the radiofrequency range (e.g., over 10 kHz) can be used for ablation.  
Alternatively, ablation may be achieved by any other suitable means, for example any thermal  
means or cryoablation means.

Preferred intravascular sites for stimulation of parasympathetic nerves include the right

1 pulmonary artery, the superior vena cava, and the coronary sinus. Stimulation at these sites  
is useful to control a variety of arrhythmias and tachycardias, including atrial fibrillation and  
ventricular tachycardia.

5 The system comprises a catheter, preferably a steerable catheter having a tip section  
containing one or more electrodes. The catheter may be any type that can be safely placed  
and maintained in a desired location in a blood vessel without unduly impeding blood flow.  
A preferred catheter for use in the invention has a variably expandable electrode section, most  
preferably a basket catheter having a basket assembly at the catheter's distal end. The basket  
10 assembly comprises a plurality of splines connected at their proximal and distal ends, at least  
one and preferably all splines comprising at least one electrode. The basket assembly is  
movable between a collapsed arrangement and an expanded, "bowed-out" arrangement.  
Preferably, the basket assembly, in its expanded arrangement, has a length of from about 2  
cm to about 6 cm, preferably from about 2 to about 4 cm and a diameter of from about 10  
15 to about 30 mm, preferably about 10 to about 20 mm. The splines of the basket catheter may  
carry one or more electrodes or may form electrodes themselves. In a preferred embodiment,  
each spline has an uninsulated central section which can serve as an electrode and one or more  
ring or wrapped electrodes on the insulated end portions of the spline. The basket  
arrangement allows very precise and stable localization of stimulation.

20 The system further comprises a low frequency pulsed signal generator electrically  
connected to the stimulating electrode for generating a stimulating signal, a monitor and/or  
display for recording and/or displaying the patient's heartbeat rate and one or more indifferent  
electrodes. In a particularly preferred embodiment of the invention, the system further  
comprises a programmable controller which is electrically connected to the pulse generator  
and to a sensor which senses the heartbeat rate of the patient. The controller, when activated,  
25 is programmed to stimulate each electrode of the electrode array to determine which is closest  
to the nerve and to vary, preferably in a stepwise fashion, one or more of the intensity,  
frequency or pulse duration of the stimulating signal to achieve the desired lowering of the  
heartbeat rate.

30 The present invention avoids the disadvantages of previous therapies. It provides a  
consistent and stable means for transvascular electrical stimulation and/or ablation  
(denervation) that affects cardiac parasympathetic and sympathetic nerves, effecting a decrease  
in the rapid atrial and ventricular responses during atrial fibrillation and other tachycardias  
without affecting ventricular contractility. The invention's transvenous approach to  
parasympathetic or sympathetic nerves offers an improved opportunity for acute and chronic  
35 ventricular rate control during atrial or ventricular tachycardia or fibrillation and other  
arrhythmias without concurrent stimulation of the heart muscle itself, and without the use of  
contraindicated drugs. Unlike previous intravascular stimulation efforts, the expandable or  
basket catheter of the invention allows long term, stable placement of the electrode for

1 accurate, repeatable stimulation at the desired location. Additionally, the short pulse duration  
reduces the risk of unwanted myocardial stimulation.

#### DESCRIPTION OF THE DRAWINGS

5 These and other features and advantages of the present invention will be better  
understood by reference to the following detailed description when considered in conjunction  
with the accompanying drawings wherein:

FIG. 1: A schematic of a preferred system for regulating the heart rate of a patient.

FIG. 2A: Enlarged view of the distal end of the catheter of the system shown in  
Fig. 1.

FIG. 2B: Enlarged view of the distal end of a preferred catheter used for ablation,  
having splines uninsulated along their entire length.

FIG. 3: Illustration of the influence of the frequency of cardiac nerve stimuli on the  
supraventricular rate slowing effect. In this dog, nerve stimulation was applied in the superior  
vena cava with an impulse duration of \_\_\_\_ ms and an intensity of 26 V. At a frequency of  
20 Hz, the effect reached a plateau until it decreased at a frequency of 45 Hz.

FIG. 4: Cardiac nerve stimulation (PS) in the coronary sinus (CS). Surface ECG  
lead II, aVR and a right atrial appendage (RAA) recording are depicted. Atrial fibrillation  
was induced and maintained by rapid pacing from the RAA at a cycle length of 100 ms (low  
frequency, low amplitude pacing artifacts on the right of the RAA-tracing). PS was done at  
a stimulus strength of 34 V and a frequency of 20 Hz (high frequency, high amplitude  
electrical artifacts can be seen on the left of the RAA-tracing). The cycle length values within  
the figure refer to the longest and shortest R-R interval during AF with PS (1976 and  
1440 ms, respectively) and when PS was terminated (arrow, 600 and 260 ms, respectively).

FIG. 5: Effect of stimulus strength (SST) on ventricular rate slowing during cardiac  
nerve stimulation (PS) in the coronary sinus. The average R-R interval during atrial  
fibrillation (AF) is plotted versus the SST. The SST significantly affected the R-R interval  
during AF ( $p < 0.001$ , ANOVA). The mean R-R interval at each SST was also compared to  
the R-R interval without PS ( $^*p < 0.05$ ). Of note, during epicardial PS the threshold for a  
ventricular slowing effect during AF was considerably lower than during intravascular PS.

FIG. 6: Cardiac nerve stimulation in the right pulmonary artery. Surface ECG leads  
II and aVR are depicted. The offset of nerve stimulation is indicated by the vertical arrow.

1 The electrical artifacts of cardiac nerve stimulation can be seen as higher voltage, high  
frequency signals on the left in the ECG tracings. The smaller pacing artifacts (cycle length  
100 ms) for the induction and maintenance of atrial fibrillation (AF) are hidden by the nerve  
stimulation artifacts but can be seen after cessation of cardiac nerve stimulation (arrow). At  
5 a cardiac nerve stimulus intensity of 27 V (stimulus frequency: 20 Hz, stimulus duration: 0.05  
ms) atrio-ventricular conduction during atrial fibrillation was substantially prolonged resulting  
in marked ventricular pauses (longest 3016 ms, shortest 2008 ms). After nerve stimulation was  
terminated, a rapid ventricular response (longest: 672 ms, shortest: 452 ms) resumed almost  
immediately.

10

FIG 7: Effect of stimulus strength (SST) on ventricular rate slowing during cardiac  
nerve stimulation (PS) in the right pulmonary artery (RPA). The average ventricular rate  
interval (R-R interval) during atrial fibrillation (AF) is shown on the ordinate whereas the  
abscissa represents the SST. With increasing SST the R-R interval during AF was lengthened  
15 ( $p < 0.001$ , ANOVA). Individual values of the R-R interval at each SST were compared to the  
R-R interval without PS ( $*p < 0.05$ ).

FIG. 8A: Cardiac nerve stimulation in the superior vena cava (SVC). Surface ECG  
leads I, II and a VF and a recording of the stimuli (stim) delivered to the basket catheter are  
20 depicted. Atrial fibrillation was induced and maintained by rapid pacing from the RAA at a  
cycle length of 100 ms (low frequency, low amplitude electrical artifacts). The onset of  
parasympathetic nerve stimulation (PS) is indicated by a vertical arrow. At a PS intensity of  
13 V (stimulus frequency of 20 Hz, the shortest R-R interval during atrial fibrillation  
prolonged from 352 ms to 384 ms and the longest R-R interval from 408 to 1464 ms.

25

FIG. 8B: Increasing the stimulus amplitude to 27 V led to an even greater increase of  
the R-R intervals (shortest: 272 ms to 1008 ms; longest: 380 ms to 2336 ms). The onset of  
parasympathetic stimulation is indicated by vertical arrow.

30 FIG. 9: Effect of stimulus strength (SST) on ventricular rate slowing during cardiac  
nerve stimulation (PS) in the superior vena cava (SVC). The average ventricular rate interval  
(R-R interval) during atrial fibrillation (AF) is shown on the ordinate whereas the abscissa  
represents the SST. A substantial prolongation of the R-R interval with increasing SST was  
observed ( $p < 0.001$ , ANOVA). Individual values of the R-R interval at each SST were  
35 compared to the R-R interval without PS ( $*P < 0.05$ ).

FIG. 10A: Effect of intermittent cardiac nerve stimulation on atrioventricular  
conduction during atrial fibrillation. Surface ECG lead II and aVR and an epicardial recording



1 from the right atrial appendage (RAA) are shown. Trains of 200 Hz stimuli, each lasting 10  
ms were delivered at a train rate of 200/min. These trains can be seen as large regular  
electrical artifacts in the right atrial appendage (RAA) recording. atrial fibrillation (AF) was  
5 induced and maintained with rapid atrial pacing (cycle length 100 ms, high frequency, low  
amplitude pacing artifacts in the RAA recording). The onset of nerve stimulation is indicated  
by a horizontal arrow in the RAA tracing. At a stimulus strength of 34 V, intermittent,  
regular nerve stimulation markedly reduced the ventricular response during atrial fibrillation  
(longest R-R = 1784 ms; shortest R-R = 1120 ms).

10 FIG. 10B: This negative dromotropic effect depended on the train rate. At the  
beginning, trains were delivered at a shorter but irregular cycle length (frequent pulsing)  
resulting in a notable ventricular rate slowing during atrial fibrillation (longest R-R = 1900  
ms; shortest R-R = 630 ms). When the pulsing rate became infrequent and irregular (right side  
of the recording), the ventricular rate slowing effect during atrial fibrillation was considerably  
15 less (longest R-R = 600 ms; shortest R-R = 265 ms).

FIG. 11: Continuous parasympathetic cardiac nerve stimulation in the coronary sinus  
over 20.5 hours. The ventricular rate (R-R interval) during atrial fibrillation (AF) is plotted  
versus time. After a slight decrease of the rate slowing effect during the initial 2 hours the rate  
20 slowing effect persisted over the remaining 20.5 hours. There was always a reserve of the  
negative dromotropic effect as demonstrated by a further prolongation of the R-R interval  
when the stimulus voltage was intermittently increased from 25 to 39 V.

## 25 DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a system comprising a minimally invasive catheter and  
low frequency pulsed signal generator for treating and preventing atrial and ventricular  
tachycardia and cardiac arrhythmias by specific stimulation of parasympathetic or sympathetic  
nerves innervating the heart. The invention also provides a system comprising a minimally  
30 invasive catheter and an ablation signal generator for treating and preventing tachycardia by  
specific ablation of parasympathetic and/or sympathetic nerves innervating the heart. As used  
herein, "tachycardia" means the rapid beating of the heart, and can include fibrillation and  
flutter. "Fibrillation" means an uncoordinated contraction of cardiac muscle, leading to  
inefficient pumping of the heart. "Flutter" means an extremely rapid beating.

35 A preferred system in accordance with the present invention is shown in Figs. 1 and  
2. The system comprises a steerable catheter 10, having an expandable basket assembly 12  
at its distal end. The basket assembly 12 carries a plurality of electrodes 14 and 16 which are  
electrically connected to a signal generator 18 by electrode lead wires (not shown) which

1 extend through the interior of the catheter and electrical connection 19. One or more  
indifferent electrodes 20 which are placed on the patient's skin are also electrically connected  
to the signal generator 18 by electrical connection 21.

5 The signal generator 18 is capable of generating a signal having a frequency from about  
1 to about 20 Hz, preferably about 20 to about 30 Hz and having an intensity of from about  
1 to about 150 volts, preferably from about 8 to about 15 volts and a pulse duration of from  
about 1 microsecond to about 10 milliseconds, preferably from about 50 to about 600  
microseconds.

10 One or more sensors 22 are provided for monitoring the heartbeat of the patient. The  
sensors are electrically connected via line 23 to a recorder/display 24 for recording and/or  
displaying the patient's heartbeat, preferably in the form of a conventional electrocardiogram  
or the like. In the embodiment shown, a programmable controller 26 is electrically connected  
to the signal generator 18 via line 25 and to sensors 22, e.g., via line 27 to recorder/display  
24.

15 The catheter 10 comprises an elongated tubular catheter body 30, a tip section 32 at the  
distal end of the catheter body 30 and a control handle 34 at the proximal end of the catheter  
body 30. The catheter body 30 comprises an elongated tubular construction having a single,  
central or axial lumen. The catheter body 30 is flexible, i.e., bendable, but substantially non-  
compressible along its length. The catheter body 30 preferably comprises a tubular wall of  
20 high-strength braided stainless steel or other high-strength wire or fiber, sandwiched between  
inner and outer layers of firm, yet flexible, polyurethane. This high torque shaft structure  
allows a physician to control the orientation of the electrode basket by rotating the catheter  
body 30 where it enters the patient's body, which is usually at the groin or neck. The catheter  
body 30 preferably further comprises a nylon stiffening sleeve lining the interior of the tubular  
25 wall. A suitable construction of the catheter body is disclosed in U.S. Patent No. 5,827,278  
which is incorporated herein by reference. The outer diameter of the catheter body 30 is not  
critical but is preferably no more than about 8 French and more preferably no more than  
about 7 French. Likewise, the thickness of the outer wall is not critical.

30 The catheter tip section 32 comprises a short section of flexible tubing preferably  
having a diameter of about 6-7 French, and having a pair of off axis lumens. At the distal  
end of the tubing of the tip section, there is provided an expandable basket assembly 36. A  
preferred basket assembly construction is disclosed in U.S. Patent No. 5,772,590, which is  
incorporated herein by reference. In such a construction, the basket assembly has five arms  
and a central puller wire. The arms are fixed at their proximal ends to a proximal fitting and  
35 also fixed at their distal ends to a distal fitting. The proximal fitting which has a central  
opening, is received by and fixed by glue or the like in a recess in the distal end of the tubing  
of the catheter tip section. The arms comprise a backbone made of metal, e.g., Nitinol, of  
semi-circular cross section. The metal backbones are completely or partially covered with an

1 insulation coating. One or more electrodes may be carried on the arms. In a preferred  
embodiment suitable for ablation, the entire surface of the spline is uninsulated.

5 A particularly preferred basket assembly 12 is shown in Fig. 2. In this embodiment,  
the outer surface of the middle half of the metal backbone of the arms (only two arms of five  
are shown) are exposed to form electrodes 14. Additionally, each arm contains a ring-type  
electrode 16 on the insulated portions of the arm both distally and proximally to the exposed  
backbone portion. Preferred ring-type electrodes are formed by wrapping a lead wire around  
the insulated coating a number of times and stripping the lead wire of its own insulated  
coating on its outwardly facing surfaces. Such electrodes are disclosed for example in U.S.  
10 Patent No. 5,772,590.

The particular construction of Figure 2 involving an electrode configuration of partially  
exposed arms and adjacent wrapped electrodes is presently preferred because it has been found  
to increase current density in a small area, allowing up to a 50% decrease in the current  
needed to stimulate the nerve. This reduces the risk of tissue damage and other adverse  
15 effects. In its expanded arrangement, the basket assembly is preferably no more than about  
6 cm long and preferably from about 2 to about 4 cm long. Also in its expanded  
arrangement, the diameter is adjustable to from about 10 to about 30 mm.

The catheter comprises a steering mechanism, for example, as described in U.S. Patent  
No. RE 34,502 and U.S. Patent Application Nos. 09/157,055 (filed September 18, 1998),  
20 09/130,359 (filed August 7, 1998), and 08/924,611 (filed September 5, 1997), which are  
incorporated herein by reference. The steering mechanism comprises a puller wire (not  
shown) which extends from a proximal end in the handle through the catheter body and into  
an off axis lumen in the catheter tip section. Within the catheter body, the puller wire extends  
through a closely wound coil that is bendable but substantially compressible. The coil is fixed  
25 near the proximal and distal ends of the catheter body and prevents deflection of the catheter  
body.

The distal end of the puller wire is anchored in the tip section adjacent the proximal  
end of the basket. The proximal end of the puller wire is anchored to a movable member in  
the handle which can be moved relative to the catheter body. Proximal movement of the  
movable member relative to the catheter body. Proximal movement of the movable member  
30 relative to the catheter body results in deflection of the catheter tip section.

A second puller wire 36 extends through the catheter body, catheter tip section and is  
fixed to the distal fitting 44 of the basket. The second puller wire extends out of the proximal  
end of the catheter and into the handle for applying a proximally directed force to the puller  
wire. When the puller wire is moved proximally relative to the catheter body, the basket  
35 expands outwardly. Outward expansion of the basket forces the arms against the vessel walls,  
thereby impeding the motion of the arms relative to each other and resisting shifting of the  
basket within the vessel. Such a second puller wire arrangement is disclosed, for example,

1 in U.S. Patent No. 5,772,590.

5 The handle 34 may be of any suitable construction for manipulating a pair of puller wires. Preferably the handle has a pair of movable members to which the puller wires attach. Manual movement of the movable members results in longitudinal movement of the puller  
10 wires relative to the catheter body. Manipulation of one puller wire provides deflection of the tip section. Manipulation of the second puller wire provides expansion or elongation of the basket. Preferred handles and steering mechanisms for the catheter are described in U.S. Patent Application No. 09/130,359 (filed August 7, 1998), and U.S. Provisional Patent Application No. 60/133,709 (filed May 12, 1999), which are also incorporated herein by reference.

15 It is understood that any suitable steering mechanism may be used. Alternatively, it is understood that the invention may be practiced without any steering mechanism and/or without the use of a puller wire mechanism for expanding or elongating the basket. As to the latter, the basket may be expanded and contracted, for example, by moving the guarding  
20 sheath proximally off of the basket or distally over the basket.

It is understood that any suitable catheter that can suitably maintain a stimulating electrode at an intravascular location adjacent a parasympathetic or sympathetic nerve can be used. Stable placement means that the electrode remains relatively immobile for the time period of stimulation, so that one or repeated stimuli are applied to the same area, and the  
25 nerve fibers receiving the stimuli receive approximately the same stimulus intensity from identical stimulation pulses. If such a catheter comprises a basket assembly, any suitable basket assembly may be used. That is, the number and type, e.g., semi-circular cross section, of arms may vary as desired. Likewise, the number and type of electrodes on the arms may vary. If desired, the metal backbones of the arms may be completely exposed or completely  
30 covered. The tip section may comprise a single lumen rather than the two described above or, in the alternative, may comprise three or more lumens. Likewise, the catheter body may comprise more than one lumen if desired.

If desired, a non-basket catheter may be used. If so, it is preferred that the catheter comprise some mechanism for anchoring the stimulating against the wall of the blood vessel  
35 it is in. Such mechanisms include extendable corkscrew anchors. Examples of suitable anchoring mechanisms are disclosed in U.S. Patent No. 5,431,168, which is incorporated herein by reference.

While it is presently preferred to use a guiding sheath, if the catheter comprises a mechanism for expanding and contracting the basket independent of the guiding sheath, a  
40 guiding sheath may not be required. This is particularly true if the catheter is steerable.

The catheter 10 is disposed within an outer guiding sheath 40 for placement at the desired intravascular location. The guiding sheath 40 covers the arms of the basket assembly internally in a collapsed position so that the entire assembly, consisting of the catheter 10 and

1 guiding sheath 40, can be passed down a vein or artery to a desired location. To reach the  
desired intravascular location, the catheter and guiding sheath are inserted into a blood vessel  
and then guided to the desired site. During this procedure, the tip may be deflected as needed  
by manipulation of the first puller wire. Once the distal ends of the catheter 10 and guiding  
5 sheath 40 reach the desired location, the guiding sheath 40 is withdrawn. The second puller  
wire is then manipulated so that the arms of the basket assembly flex outwardly into their  
expanded arrangement. In such an arrangement the arms and the electrodes contact the walls  
of the blood vessel in which they are located.

Once the catheter basket is at the desired location, the controller 26 activates the signal  
10 generator 18 to transmit signals sequentially to each of the electrodes on the basket and to  
determine, based on signals received from the sensors 22 (indicating a response by the heart  
to the transmitted signals) which of the electrodes is closest to the nerve. If there is no  
response by the heart, the controller activates the signal generator to transmit a second signal  
15 sequentially to each of the electrodes, said second signal being different from the first signal  
in intensity, frequency or duration, preferably intensity. The controller continues this process  
until a response by the heart is received and the electrode(s) closest to the nerve in question  
is identified. If after a select period of time, if no response from the heart is sensed, the  
controller provides a signal, e.g., audible or visual, to the physician indicating that the  
20 electrode(s) are not sufficiently close to the desired nerve and that the catheter needs to be  
repositioned.

Once the electrode(s) nearest the desired nerve has been identified, the controller  
activates the pulse generator to transmit a stimulating signal to the identified electrode. If the  
response by the heart is insufficient, e.g., not enough slowing, the controller activates the  
pulse generator to vary the stimulating signal in one or more of the intensity, frequency and  
25 pulse duration, preferably in a stepwise fashion, until the desired slowing of the heartbeat rate  
is achieved. For example, a signal having an intensity sufficient to elicit a response from the  
heart may slow the heartbeat rate to some degree but not as much as is desired. Accordingly,  
the signal may be increased stepwise in intensity until the desired amount of slowing is  
achieved.

30 The parasympathetic nervous system produces its cardiac action primarily via vagal  
nerve fibers leading to cardiac ganglia. Sympathetic nerve fibers emerge from multiple  
cervical and paravertebral ganglia to provide a network of postganglionic nerve endings to the  
atria, ventricles, sinus node, and atrioventricular node. The terms "nerve" and "nerve fiber"  
as used herein includes a single neuron, a nerve, nerve ending(s), or nerve bundle, and if it  
35 is described as "autonomic," may be comprised of all parasympathetic, all sympathetic, or  
mixed parasympathetic and sympathetic fibers.

Because of the pattern of cardiac autonomic innervation, the invention can be practiced  
at numerous sites within the vasculature. In fact, any intravascular site which is adjacent to

1 an autonomic fiber that innervates the heart is a potential site for the stimulation method of  
the invention. As used herein, "intravascular" means within the venous or arterial circulatory  
system, including blood vessels of all descriptions and chambers of the heart. When referring  
to "intravascular stimulation" in describing the method of the invention, it is meant stimulation  
5 from within the circulatory system resulting in (transvascular) stimulation of a tissue of  
interest. "Transvenous" or "transvascular" means across a blood vessel or across the wall of  
a cardiac chamber (including the connective, adipose, muscle, neural, and other associated  
tissue). "Stimulation" means a stimulus, usually electrical, which causes depolarization of a  
cell or cells, or portion of a cell, contraction, excitation as measured by e.g., calcium or  
10 sodium influx into the cell, or an altered membrane potential across a cell.

Appropriate sites for stimulation are those adjacent to cardiac autonomic nerves.  
Preferably the sites are sufficiently far from myocardial muscle that the muscle is not at risk  
of contraction during stimulation.

However, for some preferred sites, e.g., the coronary sinus, myocardial muscle is  
15 adjacent and can be stimulated by the autonomic stimulation. This is rarely a problem when  
the atria are in fibrillation, because the stimulation is incapable of causing coordinated atrial  
contraction.

Potential stimulation sites can be initially selected by reference to general anatomy;  
blood vessels of sufficient diameter for catheter access which are known to have autonomic  
20 fibers innervating the heart running nearby or adjacent are suitable candidates. Care must be  
taken, of course, to select locations with nerves that primarily innervate the area of interest  
so that other innervated areas are not affected. For example, three preferred intravascular  
parasympathetic sites at which a substantial reduction in ventricular rate during atrial  
fibrillation can be obtained are the ostium of the coronary sinus, the right pulmonary artery  
25 and the superior vena cava. Sympathetic bundles may be stimulated from discrete sites, for  
example, transvascularly from the aorta or the main pulmonary artery to the sympathetic fibers  
that run alongside. As will be apparent to one of skill in the art, the invention is not limited  
to sites directly adjacent to the heart, but can be practiced at any of the variety of sites  
(primarily thoracic) where blood vessels suitable for catheter access run parallel to or  
30 otherwise intersect with autonomic fibers serving the heart. Target fibers can thus be accessed  
from different sites on the patient, for example from near the subclavian, jugular, or azygous  
veins.

In accordance with the method of the invention, the catheter is introduced into a blood  
vessel and is guided by suitable means to a desired location. For example, fluoroscopic  
35 imaging can be used to guide the catheter to the selected site. In addition or alternatively, if  
the desired site is close to or within the myocardium, an electrode of the catheter may be used  
to sense electrical activity of the heart, such that when signals generated by the contraction  
of the cardiac muscle are detected, the sensing electrode is in the atrium. The catheter may

1 then be advanced through the heart or withdrawn to reach the desired site. If the target site  
is just outside the heart, the catheter may be advanced or withdrawn until no myocardial  
contraction is detected. For example, if the target is the right pulmonary artery, the catheter  
would be advanced through the atrium, the tricuspid valve, and the right ventricle before  
5 exiting the heart and entering the right pulmonary artery. When contraction of the heart is  
no longer sensed, the catheter would be in a suitable position to begin testing for the desired  
stimulation location. Likewise, if the target is the superior vena cava, for example, sensing  
is performed from the catheter until atrial impulses are detected, indicating that the catheter  
is in the atrium. From that point, the catheter is slowly withdrawn until atrial signals are no  
10 longer detected. This would indicate that the catheter is in the superior vena cava.

Once a site is selected and the catheter is guided to the vicinity, accurate placement is  
made by slowly advancing or withdrawing the catheter, expanding it to hold it in place, and  
testing each electrode to identify the one closest to the selected nerve. If none of the arms  
are suitably close to the nerve, the expanded basket is contracted and moved slightly to  
15 another location. It is re-expanded and the electrodes re-tested. This process is repeated until  
adequate nerve stimulation is achieved.

Stimulation can be optimized by varying the intensity, frequency, polarity, and/or pulse  
duration of the signal. Of particular usefulness is changing the signal strength. A graded  
response of the ventricular rate during atrial fibrillation ranging from slight slowing to  
20 complete AV block can be accomplished. The desired level will be somewhere in between  
these extremes, and will vary depending on the patient's condition. Parameters and protocols  
for nerve stimulation can be any that produce the desired sympathetic or parasympathetic  
effects on the heart, and can be adjusted as needed for different patients or during an  
individual patient's treatment.

25 In general, stimulus pulse duration, amplitude, polarity, and/or intensity can be  
modified. The pulse duration can be between about 1 microsecond to about 10 milliseconds,  
preferably about 100  $\mu$ sec (0.1 ms); the frequency will be from about 1 to about 200 Hz,  
preferably from about 20 - 45 Hz; and the stimulus intensity will be from about 1 to about  
150 V, preferably from about 8 to about 15 V. The range of stimulation frequencies  
30 possible, including the optimum range in the preparations tested is shown in Fig. 3.  
Frequencies between about 20 and 45 Hz showed the most preferable supraventricular rate  
slowing. The optimum signal will depend on the current density achieved at the stimulation  
site, the voltage drop across the stimulating equipment to the delivery site, and other factors  
well known to those of skill in the art. Lower voltages and frequencies are generally  
35 preferred, since they reduce the risk of tissue damage or any possible discomfort in patients  
arising from the stimulation. Shorter duration pulses are generally preferred because they  
reduce the possibility of depolarizing nearby muscle fibers.

If the selected stimulation site is adjacent to cardiac muscle, contraction of the muscle

1 in response to the nerve stimulation can be avoided by timing the stimuli to coincide with the  
myocardial refractory period (when no amount of stimulation will induce contraction of the  
muscle). If this is done, a stronger signal may be used. If desired, concurrent pacing of the  
atria or ventricles can be performed to time the nerve stimulation to the heartbeat or refractory  
5 period of the muscle. Concurrent pacing can be performed with the same or a different  
catheter or electrode(s), and can be within the heart or vasculature or externally using any  
known methods. Likewise, recording or monitoring can be accomplished with the same or  
different electrodes or catheters.

The system and methods of the invention can be used to ablate sympathetic and  
10 parasympathetic nerves if necessary. Sympathectomy is indicated in certain patients, for  
example those with contraindications to  $\beta$ -blockers. Selective sympathetic denervation,  
performed by transvascular ablation using the method of the invention, can reduce these  
patients' risk of sudden death from acute arrhythmias. Selective parasympathetic denervation  
may be indicated in patients with atrial tachycardia or fibrillation induced or maintained by  
15 excessive vagal nerve stimulation. A denaturing or ablating stimulus (e.g., radiofrequency  
or cryoablation) is applied across the vessel wall to the sympathetic fibers at any desired  
location. Preferably, sites are selected where a purely or nearly pure sympathetic or  
parasympathetic branch runs very close to the vessel, and where there are few other nerves  
or other sensitive tissues. Ablating stimulation is applied until conduction in the fiber is  
20 impaired or ceases altogether. This can be monitored by any means, including recording from  
the heart to observe a change in heart rate. Such ablation is irreversible, and can be very  
selectively performed by first stimulating the nerve to determine its innervation sites and  
selecting an ablation location that maximizes the desired effect while minimizing unwanted  
ablation.

### 25 Example 1

#### Surgical Preparation and Parasympathetic Cardiac Nerve Stimulation and Measurement

##### Methods

30 All animal studies were carried out in accordance with the guidelines for animal care  
and experimentation established by national agencies and were approved by the Research and  
Development Committee of the Department of Veterans Affairs Medical Center, Oklahoma  
City, Oklahoma. In 33 adult mongrel dogs (weight 18-30 kg) anesthesia was induced with  
intravenous sodium pentobarbital (30 mg/kg body weight). During the experiment, 50 to 100  
mg were injected as needed to maintain a sufficient depth of anesthesia. The dogs were  
35 intubated with a cuffed endotracheal tube and ventilated with room air using a positive  
pressure respirator (Harvard Apparatus Co., Natick, MA, USA). A cannula was inserted into  
the left external jugular vein for fluid and drug delivery. Arterial blood pressure was  
monitored through a cannula in the right femoral artery. A quadripolar catheter with 2 mm



1       interelectrode spacing was introduced into the left common carotid artery and advanced to the  
aortic root to record His bundle activity as described elsewhere (14, herein incorporated by  
reference). A right lateral thoracotomy was performed at the fourth intercostal space. After  
pericardiotomy the right atrium and the right ventricle were exposed. Pairs of plunge wire  
5       electrodes were inserted into the right atrial appendage and right ventricular apex for atrial and  
ventricular pacing, respectively, and local electrogram recording. Surface ECG lead II and  
aVR were monitored continuously. All tracings were amplified and digitally recorded using  
a computer-based Bard Labsystem (CR Bard Inc., Billerica, MA, USA). ECG filter settings  
were 0.01 to 250 Hz, whereas bipolar electrograms were filtered at 30 to 250 Hz.

10       A custom designed 7 French basket catheter, a preferred embodiment of the catheter  
of the invention, was used for autonomic nerve stimulation (Cordis Webster Corp., CA). The  
catheter used in the present study used each arm as the electrode ("multiple-spline catheter;"  
portions of the arms were uninsulated). Bipolar electrical stimulation was done between  
adjacent arms of the basket. Periods of electrical stimulation lasting 10 seconds were  
15       delivered by means of a Grass stimulator (Astro-Med, Inc. / Grass Instruments Division, West  
Warwick, RI) at a stimulation frequency of 20 Hz and a pulse duration of 0.05-0.1 ms. This  
level of stimulation has previously been demonstrated to be suitable for epicardial  
parasympathetic nerve fiber stimulation (10, herein incorporated by reference). Cardiac nerve  
stimulation at each of three stimulation sites, i.e., the coronary sinus, the right pulmonary  
20       artery, and the superior vena cava, was performed during atrial fibrillation. Atrial fibrillation  
was induced and maintained by constant rapid pacing at a cycle length of 100 ms from the  
electrodes in the right atrial appendage.

#### Group 1: Stimulation in the Coronary Sinus (n=10)

25       For parasympathetic stimulation in the coronary sinus, the catheter was introduced  
through the right or left external jugular vein. It was then advanced into the right atrium under  
fluoroscopic guidance. Positioning into the os of the coronary sinus was performed as  
described previously (13, incorporated by reference). When the coronary sinus had been  
entered, the basket was expanded to hold the catheter in a stable position against the  
30       endovascular surface. Stimulation over each adjacent pair of electrode arms was then  
attempted while the stimulus strength (SST) was increased stepwise from 7 to 50 V. If no  
visible slowing of the ventricular rate during atrial fibrillation was observed, the basket was  
contracted and the catheter gently rotated or advanced further into the coronary sinus until an  
effective stimulation site was found.

#### Group 2: Stimulation in the Right Pulmonary Artery (n = 6)

For placement of the catheter in the right pulmonary artery the basket catheter was  
introduced through a purse string suture in the right ventricular outflow tract. It was then

1 advanced under fluoroscopic control into the right pulmonary artery. Under fluoroscopy, the  
basket was positioned between the aorta and the atrial channel between the superior vena cava  
and inferior vena cava; however, electrode placement need not be done under fluoroscopic  
conditions. The sinus rate slowing was then assessed by stimulation over each adjacent pair  
5 of electrode arms at 40 V. If no visible ventricular rate slowing during atrial fibrillation  
occurred, the basket was contracted and withdrawn stepwise. Stimulation was repeated until  
a noticeable drop in ventricular rate during atrial fibrillation was achieved.

#### Group 3: Stimulation in the Superior Vena Cava (n = 6)

10 For stimulation in the superior vena cava, the catheter was introduced through the right  
or left external jugular vein until a right atrial electrogram was recorded. The catheter was  
then withdrawn to a site at which no atrial signal was recorded. At this point the basket was  
expanded and the ventricular rate slowing effect during induced atrial fibrillation was assessed  
by stimulation over each adjacent electrode pair at 40 V. If no slowing effect was observed,  
15 the catheter was withdrawn and stimulation was repeated until a slowing response was  
obtained. A successful intravascular stimulation site was located in the proximal right  
pulmonary artery.

Once an effective coronary sinus, right pulmonary artery or superior vena cava site was  
identified, neural stimulation was started at 2 V and thereafter stepwise increased to a  
20 maximal voltage of 40 V. R-R intervals during cardiac nerve stimulation were measured in  
surface ECG leads II and aVR. At each stimulus intensity, 10 consecutive R-R intervals after  
the onset of cardiac nerve stimulation were measured for calculation of the mean R-R interval.

#### 25 Measurement of Sinus Rate Slowing and Effective Refractory Period for Intravascular Stimulation

In those dogs in which stimulation was performed at the superior vena cava and right  
pulmonary artery sites, the atrial and ventricular effective refractory periods and AV  
conduction during cardiac nerve stimulation were assessed. A-A intervals during  
parasympathetic stimulation at 40 V were measured in the right atrial appendage electrogram.  
30 The A-A intervals of 3 consecutive beats were taken for calculation of the mean A-A interval.  
Right atrial and right ventricular ERPs were determined at baseline and during cardiac nerve  
stimulation at the right pulmonary artery and superior vena cava sites by applying cardiac  
parasympathetic stimulation at an intensity of 40 V. For atrial and ventricular pacing, 2 ms  
rectangular pacing stimuli at twice the diastolic pacing threshold were delivered by a  
35 Radionics stimulator (Radionics, Inc., Burlington, MA) at the right atrial and the right  
ventricular pacing site using the extrastimulus technique. A train of 8 stimuli was delivered  
at a cycle length of 400 ms followed by a premature stimulus starting with a coupling interval  
of 350 ms. The premature stimulus was then decreased in 10 ms steps until no propagated

1 response was observed in the surface ECG or the local intracardiac electrogram. The longest  
coupling interval  $A_1-A_2$  ( $V_1-V_2$ ) of the premature beat that did not result in a propagated  
response was defined as the ERP at that stimulation site.

5 Long-term Stability of the Slowing Effect due to Parasympathetic Stimulation at the Coronary  
Sinus

Long-term efficacy of cardiac nerve stimulation at the coronary sinus site was also  
evaluated. For this purpose, in an additional dog, continuous parasympathetic stimulation was  
maintained at a stimulus strength of 25 V over 20.5 hours during pacing induced atrial  
10 fibrillation. In this dog only, a left carotid arterial line and a right jugular access for  
introduction of the basket catheter were used. A thoracotomy was not performed. Every half  
hour the mean value of 10 consecutive R-R intervals during cardiac nerve stimulation was  
calculated. The stimulus voltage was then increased for 30 seconds to 39 V and another 10  
consecutive R-R intervals were measured during this period. Both values were then compared  
15 to 10 consecutive R-R intervals during a 30-second stimulation pause.

Pharmacological Tests and Cervical Vagal Nerve Cutting

In one dog of each of the three study groups, 2 mg of atropine were injected  
intravenously and parasympathetic stimulation was attempted again. In another dog of each  
20 subgroup, both cervical vagal nerves were cut before parasympathetic stimulation was  
repeated. Also, in one dog of each study group, parasympathetic stimulation was repeated after  
topical application of 1% lidocaine on the outer surface of the proximal coronary sinus, close  
to the junction with the inferior vena cava.

25 Statistical Analysis

All data are expressed as mean  $\pm$  SD. In each group, repeated measure ANOVA was  
used to test whether the stimulus strength affected the ventricular rate during atrial fibrillation.  
The rate slowing effect at a given stimulus strength was compared to baseline values without  
parasympathetic stimulation applying a Wilcoxon matched pairs signed-rank test. In the dog  
30 in which a 20.5-hour measurement was performed, rate differences were compared using a  
Wilcoxon matched pairs signed-rank test. Refractory periods were evaluated for significance  
by means of a Student paired t-test. Probability values  $< 0.05$  were considered statistically  
significant.

35

## Example 2

### Results of Parasympathetic Cardiac Nerve Stimulation

#### A) Parasympathetic Cardiac Nerve Stimulation in the Coronary Sinus

Figure 4 shows a representative example of endovascular parasympathetic stimulation in the proximal coronary sinus. ECG leads II and aVR were recorded as well as an electrogram from the right atrial appendage. During parasympathetic stimulation with concomitantly induced atrial fibrillation, at 34 V and a frequency of 20 Hz, there was a marked increase of the R-R intervals (shortest 1440 ms, longest 1976 ms). Upon termination of parasympathetic stimulation (arrow), the longest and shortest R-R intervals were 600 and 260 ms, respectively. The lowest voltage at which at least a 50 % increase of the R-R interval occurred during atrial fibrillation was  $18 \pm 8$  V ( $312 \pm 102$  ms without parasympathetic stimulation vs.  $561 \pm 172$  ms during PS,  $p < 0.001$ ). The effect of the applied stimulus voltage on the magnitude of ventricular rate slowing was assessed by a dose-response curve as illustrated in Figure 5. Stimulus strength significantly affected ventricular rate slowing during atrial fibrillation ( $p < 0.001$ , ANOVA). The graph also shows that direct extravascular stimulation of the parasympathetic ganglia at the proximal coronary sinus region yielded a much lower parasympathetic stimulation threshold. Importantly, nerve stimulation from the epicardium during sinus rhythm with a hand held bipolar electrode effectively prolonged the AH interval without a change in the sinus rate but was subthreshold for stimulation of atrial myocardial tissue. By contrast, if nerve stimulation from the intravascular site was performed during sinus rhythm, it excited the atria, resulting in atrial fibrillation except in a few instances.

#### B. Parasympathetic Cardiac Nerve Stimulation in the Right Pulmonary Artery

Stimulation in the right pulmonary artery also decreased the ventricular rate response during atrial fibrillation as depicted in Figure 6. During parasympathetic stimulation the largest R-R interval measured 3016 ms and the shortest 2008 ms whereas on termination of parasympathetic stimulation (arrow) the longest and shortest R-R intervals were 672 and 452 ms, respectively. The ventricular rate slowing effect depended on the stimulus strength ( $p < 0.001$ , ANOVA). Increasing the stimulus strength led to a graded response of ventricular rate slowing during atrial fibrillation as shown in Figure 6. The minimal stimulus strength inducing at least a 50 % prolongation of the R-R interval during atrial fibrillation required  $23 \pm 7$  V (R-R interval of  $307 \pm 62$  ms without parasympathetic stimulation vs.  $681 \pm 151$  ms with parasympathetic stimulation,  $p < 0.001$ ). Stimulation in the right pulmonary artery also produced a shortening of the average right atrial refractory period ( $136 \pm 13$  ms without parasympathetic stimulation vs.  $96 \pm 22$  ms during parasympathetic stimulation  $n = 5$ ,  $p = 0.03$ ) whereas the right ventricular refractory period did not change significantly with neural stimulation ( $184 \pm 25$  ms with parasympathetic stimulation vs.  $186 \pm 26$  without

1 parasympathetic stimulation, n=5). Moreover, a significant slowing of sinus rate was observed  
during stimulation at the right pulmonary artery site ( $1181 \pm 306$  ms during parasympathetic  
stimulation vs.  $518 \pm 138$  ms without parasympathetic stimulation,  $n = 6$ ,  $p = 0.01$ ).

5 C. Parasympathetic Cardiac Nerve Stimulation in the Superior Vena Cava

A sufficient ventricular rate slowing during atrial fibrillation was also observed during  
parasympathetic stimulation in the proximal SVC. A typical example is shown in Figure 8A.  
At the onset of parasympathetic stimulation (arrow, stimulus strength of 13 V) the longest and  
shortest R-R intervals measured were 1464 and 384 ms, respectively, compared to baseline  
10 values of 408 and 352 ms. During parasympathetic stimulation at a stimulus strength of 22 V  
(arrow, FIG. 8B), these values increased to 2336 and 1008 ms. The lowest voltage at which  
a 50% increase of the mean ventricular cycle length during atrial fibrillation occurred was  
 $25 \pm 11$  V ( $331 \pm 139$  ms without parasympathetic stimulation vs.  $653 \pm 286$  ms during  
parasympathetic stimulation,  $p < 0.001$ ). The stimulus strength during parasympathetic  
15 stimulation significantly affected the ventricular rate during atrial fibrillation as illustrated by  
Figure 9 ( $p < 0.001$ , ANOVA). During sinus rhythm, maximal cardiac nerve stimulation led to  
a significant increase in the average sinus cycle length ( $489 \pm 154$  ms without parasympathetic  
stimulation vs.  $1056 \pm 355$  ms with PS,  $n = 6$ ,  $p < 0.001$ ) and to a shortening of the right  
atrial refractory period ( $145 \pm 55$  ms without parasympathetic stimulation vs.  $78 \pm 71$  ms with  
20 PS,  $n = 6$ ,  $p = 0.03$ ). The right ventricular refractory period did not change significantly  
during parasympathetic stimulation ( $172 \pm 26$  ms with parasympathetic stimulation vs.  $176 \pm$   
 $34$  ms without parasympathetic stimulation,  $n = 5$ ). Intermittent stimulation of the phrenic  
nerve was sometimes observed during stimulation across various splines of the electrode  
basket catheter. When the site and electrode pair was found at which electrical stimulation  
25 induced ventricular slowing during atrial fibrillation, stimulation of the phrenic nerve was  
never observed.

D. Effect of Different Nerve Stimulation Algorithms

30 Stimulation in the coronary sinus during sinus rhythm in most instances resulted in  
local atrial tissue capture, thereby inducing atrial fibrillation at a voltage that was lower than  
the one which resulted in ventricular rate slowing during atrial fibrillation. However,  
stimulation in the right pulmonary artery or superior vena cava did not capture any myocardial  
tissue.

35 Therefore, another algorithm for parasympathetic stimulation at the coronary sinus site  
was tested: trains of stimuli (stimulus frequency: 200 Hz) each lasting 10 ms were delivered  
at a train rate of 200/min (cycle length = 300 ms). These pulsed trains also excited atrial  
tissue, resulting in atrial pacing at a rate of 200/min. Importantly, 2:1 AV block was observed  
during these episodes. Without pulsed parasympathetic stimulation but with pacing from the

1 right atrial appendage site at a rate of 200/min, no AV block was present.

The efficacy of intermittent stimulation trains to slow the ventricular rate during atrial fibrillation is illustrated in Figure 10. At a stimulus strength of 34 V, intermittent pulses of parasympathetic stimulation (constant train cycle length of 300 ms, train duration 10 ms) markedly reduced the ventricular response during atrial fibrillation. A negative dromotropic effect was also achieved when the trains of stimuli were delivered irregularly as demonstrated in Figure 10B. At the beginning of the recordings trains with frequent pulsing but irregular train cycle length resulted in a notable ventricular cycle length prolongation (1900 ms longest, 630 ms shortest) during atrial fibrillation. When the pulsing was infrequent and irregular (right side of the tracings), the ventricular cycle length prolongation during atrial fibrillation was not as great (600 ms longest, 265 ms shortest).

Increasing the train cycle length from 300 ms to 500 ms at a train duration of 10 ms led to a decrease of the ventricular rate slowing effect during parasympathetic stimulation at 34 V (average ventricular cycle length of  $2105 \pm 1160$  ms at a train cycle length of 300 ms vs.  $942 \pm 294$  ms at a train cycle length of 500 ms vs.  $379 \pm 65$  ms without parasympathetic stimulation,  $n = 2$ ). The rate slowing effect also depended on the train duration as found in another 2 dogs: at a constant train cycle length of 300 ms, the decrease in average ventricular cycle length during atrial fibrillation was higher for trains lasting 100 ms ( $1325 \pm 663$  ms, SST; 150 V) than for trains with a duration of 10 ms ( $1156 \pm 566$  ms, SST: 150 V vs.  $474 \pm 91$  ms without parasympathetic stimulation,  $n = 2$ ).

#### E. Long-term Stability of the Slowing Effect due to Parasympathetic Stimulation at the Coronary Sinus

To test if there was a fading of the slowing effect during a longer stimulation period, continuous nerve stimulation in the coronary sinus was performed over 2 hours in 2 dogs. Although the mean R-R interval during atrial fibrillation after 2 hours of parasympathetic stimulation was shorter than at the onset of parasympathetic stimulation ( $644 \pm 149$  ms vs.  $778 \pm 210$  ms,  $n = 2$ ), it was still longer compared to the R-R intervals without parasympathetic stimulation ( $452 \pm 114$  ms,  $n = 2$ ). In another dog, the stability of the rate slowing effect was assessed over a 20.5-hour period as illustrated in Figure 11. The effect of ventricular rate slowing during atrial fibrillation slightly decreased over the 20.5-hour period of parasympathetic stimulation. However, after 20.5 hours there was still a considerable decrease of the ventricular rate during parasympathetic stimulation as compared to no parasympathetic stimulation. The latter was determined during a 30 s period of no parasympathetic stimulation. Of note, this small loss of efficacy over 20.5 hours was overcome if the stimulus strength was increased from 36 V to 39 V as shown in Figure 11.

#### F. Pharmacological Procedures and Cutting of the Cervical Vagal Nerves

1           At all three stimulation sites, the effect of parasympathetic stimulation on the  
ventricular response during atrial fibrillation was completely abolished after intravenous  
injection of 2 mg of atropine. Similarly, local extravascular application of lidocaine (to block  
5       nerve conduction) on the proximal coronary sinus close to the junction of the inferior vena  
cava and right atrium prevented the ventricular rate slowing effect during parasympathetic  
stimulation in the right pulmonary artery, superior vena cava and coronary sinus. By contrast,  
cutting both cervical vagal nerves did not change the parasympathetic stimulation related  
decrease of the ventricular response during atrial fibrillation at any of the 3 stimulation sites.

10       G. Comparison of Various Sites for Parasympathetic Stimulation

          Although a sufficient ventricular rate reduction was consistently achieved at each  
stimulation site, there are specific characteristics of each location which may influence the  
choice of sites for use in individual patients. Placement of an electrode catheter without a  
deflectable tip in the coronary sinus through jugular or subclavian venous access is a standard  
15       procedure during electrophysiological procedures in patients. Similarly, introduction of the  
basket catheter in the coronary sinus was achieved by a transvenous access in our study.  
However, because this approach may require some technical experience, entrance to the right  
pulmonary artery may be more readily achieved in individual patients. This is because most  
physicians may be more confident doing pulmonary catheterization, which is a standard  
20       procedure during evaluation of valvular or congestive heart disease, than coronary sinus  
catheterization. However, both the coronary sinus and the right pulmonary artery approach can  
be used with a fluoroscopy to position the catheter. On the other hand, the superior vena cava  
site was reached without fluoroscopy in the Examples, making this approach more suitable  
for an acute emergency situation in critically ill patients.

25       A limitation of continuous stimulation at the coronary sinus site is that effective  
parasympathetic stimulation may result in electrical excitation of atrial tissue. Although this  
is not relevant in the setting of chronic atrial fibrillation, it may contribute to the perpetuation  
of atrial fibrillation in patients with recent onset atrial fibrillation. An algorithm consisting of  
repetitive trains of stimuli has proved to be efficacious in slowing the heart rate during atrial  
30       fibrillation. The negative dromotropic effects were higher with more frequent or longer  
duration trains. Therefore, one can couple trains of stimuli to the QRS complex during atrial  
fibrillation to result in an automatic adjustment of the intensity of parasympathetic stimulation  
to the ventricular rate during atrial fibrillation. Moreover, in case of termination of atrial  
fibrillation, ongoing train delivery may only evoke atrial extrasystoles that are coupled to the  
35       QRS complex and may not reinduce atrial fibrillation.

          Once the catheter was positioned at any of the three stimulation sites and the basket  
was expanded, no dislocation of the catheter was observed. Theoretically, in case of  
dislocation of the stimulating catheter in the coronary sinus or right pulmonary artery catheter

1 in the right ventricle, induction of ventricular fibrillation might occur if a continuous  
stimulation algorithm is applied. This may be avoided by delivering trains of parasympathetic  
stimuli during the absolute ventricular refractory period which could be achieved by triggered  
delivery of the trains immediately after the end of the QRS complex.

### **Example 3: Ablation of Parasympathetic Nerves**

#### **A. Ablation at the Junction of the Superior Vena Cava and Right Atrium Terminates Neurally Induced Atrial Fibrillation.**

10 Atrial tissue at the junction of the superior vena cava (SVC) and right atrium (RA) has  
been implicated as the source for symptomatic atrial tachycardia and atrial fibrillation. Here,  
eight dogs were anesthetized with sodium pentobarbital, and had a basket catheter of the  
invention expanded at the SVC/RA junction for bipolar recording and pacing. Atrial  
electrograms were also recorded from close bipolar electrodes at the right atrium and left atrial  
15 appendage, along Bachmann's bundle, coronary sinus and the pulmonary veins. In order to  
avoid atrial activation during nerve stimulation, the right atrium was paced at a rate of either  
150/min or 330/min with each pacing stimulus coupled (20 msec) to a 50 msec train of high  
frequency stimuli (200 Hz, each stimulus lasting 0.1 msec). Voltages for neural stimulation  
trains were titrated from 2-40 V.

20 At an average of  $23 \pm 4$  V (mean  $\pm$  std. dev.), rapid atrial tachycardia leading to atrial  
fibrillation was induced which was characterized by early activation and continuous electrical  
activity in the vicinity of the SVC. At significantly lower voltages ( $17 \pm 6$  V,  $p=0.02$ ),  
concealed atrial ectopic beats were recorded with occasional firing from the SVC area  
showing exit block to the rest of the atria. With beta-blockade (esmolol, 1mg/kg,  $n=4$ ), the  
25 atrial fibrillation threshold increased to  $28 \pm 6$  V ( $n=3$ ,  $p=0.04$ ). In one dog, atrial fibrillation  
was no longer inducible after esmolol injection. Atropine (2mg,  $n=3$ ) completely abolished  
stimulation induced atrial premature beats, atrial tachycardia, and atrial fibrillation. Two to  
four hours after autonomic blockade, the stimulation induced arrhythmias returned.  
Radiofrequency current (70V, impedance 180-220 ohms, 60 sec,  $n=8$ ) again completely  
30 abolished the induction of atrial premature beats, atrial tachycardia and atrial fibrillation, even  
at the highest voltage (39 V). The average number of radiofrequency current ablations needed  
to achieve these results was  $2.9 \pm 1.6$  / dog.

The SVC/RA junction appears to be a site for neurally induced atrial premature beats,  
atrial tachycardia and atrial fibrillation which can be abolished by autonomic blockade or  
35 electrical ablation of parasympathetic atrial innervation. Ablation may destroy the atrial  
myocardium which is the source of the arrhythmias or the adjacent neural elements or both.



1     B. Ablation at the Inferior Vena Cava and Right Pulmonary Artery Abolishes Vagal Atrial  
          Fibrillation

5     The parasympathetic nervous system considerably shortens the atrial refractory period and can maintain atrial fibrillation. We demonstrated that intravascular radiofrequency catheter ablation of the parasympathetic nerves innervation the atria can be achieved and prevents electrically induced atrial fibrillation which was maintained by supramaximal bilateral cervical vagal nerve stimulation (VNS).

10    In six dogs, intravascular atrial denervation (IAD) was performed using intravascular radiofrequency current ablation of parasympathetic atrial nerves in the right pulmonary artery and inferior vena cava. Atrial fibrillation was induced with rapid atrial stimulation and maintained by VNS. Before and after IAD, the product of conduction velocity and atrial refractory period (AERP) was determined at seven atrial sites (high and low right atrium, proximal and distal coronary sinus and Bachmann bundle, left superior pulmonary vein) at baseline and during VNS. Before IAD, AERPs shortened from  $124 \pm 5$  ms at baseline to  $40 \pm 7$  ms during VNS ( $p < 0.001$ ). At all seven atrial sites, atrial fibrillation could be induced and maintained by rapid atrial stimulation and VNS. After IAD, vagally induced shortening of the AERPs was considerably blunted ( $125 \pm 3$  ms at baseline to  $116 \pm 5$  ms during VNS,  $p = 0.01$ ). After IAD, atrial fibrillation could not longer be induced and maintained by rapid atrial stimulation and VNS at any of the seven atrial sites. No intravascular thrombi or vessel perforation were observed after ablation.

20    The description and Examples herein show for the first time a transvenous approach to stable and consistent acute and long term parasympathetic cardiac nerve stimulation. Using the stimulation method and catheter of the invention, it has been shown that the negative dromotropic effect during intravascular coronary sinus stimulation is sufficient to cause a considerable ventricular rate slowing during atrial fibrillation. The use of the basket catheter allows rapid, consistent, and stable electrode placement at the desired site, even over long time periods. A negative dromotropic effect can also be achieved during intravascular stimulation in the superior vena cava or right pulmonary artery. In addition to a negative dromotropic effect, a negative chronotropic effect and a shortening of the atrial refractory period can be achieved in the superior vena cava and right pulmonary artery.

25    The system and method of the invention provide means to stimulate autonomic neurons innervating the heart from within the vasculature to regulate atrial and/or ventricular function. Beneficial results are achieved by significant supraventricular and ventricular rate slowing. Such treatment is particularly useful to counteract undesirable positive chronotropic effects of catecholamines during treatment of cardiogenic or septic shock, acute congestive heart failure, or in patients with rapid ventricular response during atrial fibrillation and poor left ventricular function who are not good candidates for beta blockers or calcium channel antagonists. Additionally, autonomic nerve stimulation or selective ablation is useful in

1 patients with conditions such as paroxysmal atrial fibrillation and symptomatic atrial  
tachycardia and fibrillation. The disclosed methods are superior to previously reported  
stimulation methods to correct tachycardia because they do not require surgical entry into the  
thoracic cavity, and do not require ablation of muscle.

5 The preceding description has been presented with references to presently preferred  
embodiments of the invention. Persons skilled in the art and technology to which this  
invention pertains will appreciate that alterations and changes in the described structures and  
methods can be practiced without meaningfully departing from the principle, spirit and scope  
of this invention.

10 Accordingly, the foregoing description should not be read as pertaining only to the  
precise structures and methods described and shown in the accompanying drawings, but rather  
should be read as consistent with and as support for the following claims, which are to have  
their fullest and fairest scope.

#### 15 References

1. Prystowsky EN, Benson DW, Fuster V, Hart RG, Neal Kay GN, Myerburg RJ, Naccarelli GV, Wyse DG. Management of patients with atrial fibrillation: A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology, American Heart Association. *Circulation* 1996;93:1262-1277
- 20 2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke* 1991 ;22:983-988
3. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: The Framingham Study. *N Engl J Med* 1982; 306:1018-22
- 25 4. Benjamin EJ, Levy D, Vazir SM et al. Independent risk factors for atrial fibrillation in a population-based cohort. *JAMA* 1994;271:840-844
5. Van Gelder IC, Crijns HJ. Cardioversion of atrial fibrillation and subsequent maintenance of sinus rhythm. *Pacing Clin Electrophysiol* 1997; 20 (10,2): 2675-2683
6. Brodsky MA, Allen B J, Walker CJ, et al. Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of dilated left atrium. *Am J Cardiol* 1987;60:572-575
- 30 7. Myerburg RJ, Castellanos A. Cardiac arrest and sudden death. In: Braunwald E, ed. *Heart disease: A textbook of cardiovascular medicine*, 4th edition, Philadelphia, WB Saunders 1992:756-789.
8. Vanoli E, De Ferrari GM, Stramba-Badiale M et al. Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. *Circ Res* 1991;68:1008-1014.
- 35 9. Puddu PE, Jouve R, Langlet F et al. Prevention of postischemic ventricular fibrillation

- 1 late after right or left stellate ganglionectomy in dogs. *Circulation* 1988;77:935-946.
10. Lazzara R, Scherlag BJ, Robinson MJ et al. Selective *in situ* parasympathetic control  
of the canine sinuatrial and atrioventricular node. *Circ Res* 1973; 32:393-401
11. Chen SA, Chiang CE, Tai CT et al. Intracardiac stimulation of human parasympathetic  
5 nerve fibers induces negative dromotropic effects: implication with the lesions of  
radiofrequency catheter ablation. *Cardiovasc Electrophysiol.* 1998;9: 245-252
12. Reek S, Geller JC, Hartung WM, Auricchio A. Einfluss transvenöser elektrischer  
Stimulation in der rechten Pulmonalarterie auf Sinusknotenläre und ventrikuläre  
Refraktärzeiten. *Z Kardiologie* 1999;88, Suppl 1:10
- 10 13. Murphy DA, Johnstone DE, Armour JA. Preliminary observations on the effects of  
stimulation of cardiac nerves in man. *Can J Physiol Pharmacol.* 1985;63:649-655
14. Quan KJ, Mackall JA, Biblo LA, Van Hare GF, Carlson MD. Endocardial  
parasympathic stimulation slows the ventricular rate during atrial fibrillation in humans.  
*PACE* 1996;19:647 (abstract)
- 15 15. Chiou CW, Eble JN, Zipes DP. Efferent vagal innervation of the canine atria and sinus  
and atrioventricular nodes. *Circulation* 1997;95:2573-2584
16. Thompson GW, Levett JM, Miller SM et al. Bradycardia induced by intravascular  
versus direct stimulation of the vagus nerve. *Ann Thorac Surg* 1998;65(3):637-42
17. Coumel P et al. Syndrome d'arythmie auriculaire d'origine vagale. *Arch Mal Coeur*  
20 1978;71:645-656.

25

30

35

## 1 CLAIMS

1. A method of regulating the heart rate of a patient comprising:  
inserting an electrophysiology catheter having a tip section with at least one stimulating  
5 electrode into a blood vessel and directing the catheter to an intravascular location wherein  
the at least one stimulating electrode of the catheter is adjacent a selected cardiac sympathetic  
or parasympathetic nerve;  
stabilizing the at least one electrode at said intravascular location; and  
delivering a stimulus through the at least one electrode, said stimulus selected to  
10 stimulate the adjacent sympathetic or parasympathetic nerve to thereby cause a regulation of  
the patient's heart rate.
2. The method of claim 1 wherein the stimulation causes a slowing of the heart  
rate.
- 15 3. The method of claim 2 wherein the patient is suffering from atrial or ventricular  
tachycardia.
4. The method of claim 2 wherein the patient is suffering from atrial flutter.
- 20 5. The method of claim 2 wherein the patient is suffering from atrial fibrillation.
6. The method of claim 1 wherein the intravascular location is selected from the  
group consisting of coronary sinus, right pulmonary artery, and superior vena cava.
- 25 7. The method of claim 1 wherein the catheter is steerable.
8. A method as claimed in claim 1 wherein the catheter comprises  
an elongated catheter body having proximal and distal ends and at least one lumen  
30 therethrough;  
a tip section comprising a section of flexible tubing having proximal and distal ends  
and at least one lumen therethrough, the proximal end of said tubing being fixedly attached  
to the distal end of the catheter body, said tip section further comprising a basket assembly  
at the distal end of the flexible tubing, said basket assembly comprising a plurality of arms  
35 connected at their proximal and distal ends, each arm comprising at least one electrode, said  
basket assembly having an expanded arrangement wherein the arms bow radially outwardly  
and a collapsed arrangement wherein the arms are arranged generally along the axis of the  
catheter tip section; and

1            wherein at least one arm comprises the at least one stimulating electrode.

5            9.     A method as claimed in claim 8 wherein the at least one stimulating electrode is stabilized at said intravascular location by expanding the basket assembly at that intravascular location.

10           10.    The method of claim 9 wherein the diameter of the basket assembly in its expanded arrangement is no more than about 30 mm and the length of the basket assembly in its expanded arrangement is no more than about 60 mm.

11.    A method as claimed in claim 9 wherein the length of the basket assembly in its expanded arrangement is from about 20 to about 40 mm.

15           12.    A method as claimed in claim 11 wherein the diameter of the basket assembly in its expanded arrangement is from about 10 mm to about 15 mm.

20           13.    The method of claim 1 wherein the stimulus comprises one or more electrical signals having a frequency of from about 1 Hz to about 200 Hz, an intensity of from about 1V to about 150V and a duration of from about 0.01 msec to about 10 msec.

14.    The method of claim 13 wherein the frequency of the electrical signal(s) is between about 20 Hz to about 30 Hz.

25           15.    The method of claim 13 wherein the intensity of the electrical signal(s) is from about 8V to about 15V.

16.    The method of claim 13 wherein the duration of the electrical signal(s) is from about 0.05 msec to about 0.1 msec.

30           17.    The method of claim 1 wherein the stimulation is timed to occur during a myocardial refractory period.

35           18.    The method of claim 17 wherein the refractory period is regulated by myocardial pacing.

19.    The method of claim 18 wherein the myocardial pacing is elicited from the stimulating electrode or a second electrode on the catheter.

- 1           20.    The method of claim 1 wherein the nerve is primarily parasympathetic.
21.    The method of claim 1 wherein the nerve is primarily sympathetic.
- 5           22.    A method of regulating the heart rate of a patient comprising:  
              providing an electrophysiological catheter comprising:  
                  an elongated catheter body having proximal and distal ends and at least one  
                  lumen therethrough;  
                  a tip section comprising a section of flexible tubing having proximal and distal  
10           ends and at least one lumen therethrough, the proximal end of said tubing being fixedly  
              attached to the distal end of the catheter body, said tip section further comprising a basket  
              assembly at the distal end of the flexible tubing, said basket assembly comprising a plurality  
              of arms connected at their proximal and distal ends, each arm comprising at least one  
              electrode, said basket assembly having an expanded arrangement wherein the arms bow  
15           radially outwardly and a collapsed arrangement wherein the arms are arranged generally along  
              the axis of the catheter tip section;  
              inserting the catheter into a blood vessel and directing the catheter to an intravascular  
              location, wherein the at least one electrode of basket assembly is adjacent a selected cardiac  
              sympathetic or parasympathetic nerve;  
20           expanding the basket assembly to stabilize the at least one electrode adjacent the  
              selected cardiac sympathetic or parasympathetic nerve; and  
              delivering a stimulus through the at least one adjacent electrode, said stimulus selected  
              to stimulate the adjacent sympathetic or parasympathetic nerve to thereby cause a regulation  
              of the patient's heart rate.
- 25           23.    The method of claim 22 wherein the stimulation causes a slowing of the heart  
              rate.
24.    The method of claim 23 wherein the patient is suffering from atrial or ventricular  
30           tachycardia.
25.    The method of claim 22 wherein the patient is suffering from atrial flutter.
26.    The method of claim 22 wherein the patient is suffering from atrial fibrillation.
- 35           27.    The method of claim 22 wherein the intravascular location is selected from the  
              group consisting of coronary sinus, right pulmonary artery, and superior vena cava.

- 1           28.    The method of claim 1 wherein the catheter is steerable.
29.    The method of claim 22 wherein the diameter of the basket assembly in its  
5   expanded arrangement is no more than about 30 mm and the length of the basket assembly  
in its expanded arrangement is no more than about 60 mm.
30.    The method of claim 29 wherein the length of the basket assembly in its  
expanded arrangement is from about 20 to about 40 mm.
- 10           31.    A method as claimed in claim 30 wherein the diameter of the basket assembly  
in its expanded arrangement is from about 15 mm to about 28 mm.
32.    The method of claim 22 wherein the stimulus comprises one or more electrical  
15   signals having a frequency of from about 1 Hz to about 200 Hz, an intensity of from about  
1V to about 200 V and a duration of from about 0.01 msec to about 10 msec.
33.    The method of claim 32 wherein the frequency of the electrical signal(s) is about  
20 Hz to about 30 Hz.
- 20           34.    The method of claim 32 wherein the intensity of the electrical signal(s) is from  
about 8V to about 15V.
35.    The method of claim 32 wherein the duration of the electrical signal(s) is about  
25   0.05 msec to about 0.1 msec.
36.    The method of claim 22 wherein the stimulation is timed to occur during a  
myocardial refractory period.
37.    The method of claim 38 wherein the refractory period is regulated by myocardial  
30   pacing.
38.    The method of claim 37 wherein the myocardial pacing is elicited from the  
stimulating electrode or a second electrode on the catheter.
- 35           39.    The method of claim 22 wherein the nerve is primarily parasympathetic.
40.    The method of claim 22 wherein the nerve is primarily sympathetic.

- 1           41. A method of selectively ablating a sympathetic or parasympathetic innervation  
of at least one portion of the heart of a patient comprising:  
          inserting an electrophysiological catheter having a tip section with an ablation electrode  
into a blood vessel and directing the catheter to an intravascular location wherein the ablation  
5       electrode of the catheter is adjacent to a selected sympathetic or parasympathetic nerve;  
          stabilizing the ablation electrode at said intravascular location;  
          delivering an ablation stimulus through the electrode, said ablating stimulus being  
sufficient to damage the nerve so that it no longer conducts impulses to the heart.
- 10           42. The method of claim 41 wherein the ablating stimulus comprises a  
radiofrequency stimulus.
43. The method of claim 41 wherein the ablating stimulus comprises a cryoablation  
stimulus.
- 15           44. A system to regulate the heart rate of a patient comprising:  
          a) a catheter having:  
          an elongated catheter body, the body having proximal and distal ends and at least one  
lumen therethrough;  
20           a tip section comprising a section of flexible tubing having proximal and distal ends  
and at least one lumen therethrough, the proximal end of said tubing being fixedly attached  
to the distal end of the catheter body, said tip section further comprising a basket assembly  
at the distal end of the flexible tubing, said basket assembly comprising a plurality of arms  
connected at their proximal and distal ends, each arm comprising at least one electrode, said  
25       basket assembly having an expanded arrangement wherein the arms bow radially outwardly  
and a collapsed arrangement wherein the arms are arranged generally along the axis of the  
catheter tip section, the length of the basket assembly in its expanded arrangement being from  
about 20 to about 60 mm; and  
          b) a pulse generator electrically connected to the at least one electrode in each arm  
30       of the basket assembly, said pulse generator capable of generating stimulating pulses having  
a frequency of from about 1 Hz to about 200 Hz, an intensity of from about 1V to about  
200 V and a duration of from about 0.01 msec to about 10 msec.
45. The system of claim 44 wherein the length of basket assembly in its expanded  
35       arrangement is from about 20 to about 40 mm.
46. The system of claim 44 wherein the diameter of the basket assembly in its  
expanded arrangement is from about 10 to about 30 mm.



1           47. The system of claim 45 wherein the diameter of the basket assembly in its expanded arrangement is from about 10 to about 20 mm.

5           48. The system of claim 44 wherein the frequency of the stimulating pulses is between about 20 Hz to about 30 Hz, the intensity of the electrical signal(s) is between about 8V to about 15V, and the duration of the electrical signal(s) is from about 0.05 msec to about 0.1 msec.

10           49. The system of claim 44 further comprising a heart rate monitor for monitoring the heart rate of a patient.

          50. The system of claim 49 further comprising a display for displaying the monitored heart rate of a patient.

15           51. The system of claim 49 further comprising a programmable controller electrically connected to the pulse generator and to the heart rate monitor, said controller programmed to activate the pulse generator to transmit a select stimulating pulse sequentially to each of the at least one electrode of each basket assembly arm after the catheter has been inserted into a blood vessel of a patient and placed at an intravascular location adjacent a sympathetic or  
20           parasympathetic nerve to be stimulated and for determining which of the at least one electrodes are closest to the nerve to be stimulated.

          52. The system of claim 51 wherein the controller is further programmed to, once the at least one electrode nearest the nerve to be stimulated has been determined, activate the  
25           pulse generator to transmit a stimulating signal to said nearest at least one electrode and to vary one or more of the intensity, frequency, and pulse duration of said stimulating signal to obtain a select reduction in the heart beat rate of the patient.

30           53. A catheter for use in regulating the heart rate of a patient comprising:  
          an elongated catheter body, the body having proximal and distal ends and at least one lumen therethrough;

          a tip section comprising a section of flexible tubing having proximal and distal ends and at least two lumens therethrough, at least one such lumen being off-axis, the proximal end of said tubing being fixedly attached to the distal end of the catheter body, said tip section  
35           further comprising a basket assembly at the distal end of the flexible tubing, said basket assembly comprising a plurality of arms connected at their proximal ends by a proximal fitting and at their distal ends by a distal fitting, each arm comprising at least one electrode, said basket assembly having an expanded arrangement wherein the arms bow radially outwardly

- 1 and a collapsed arrangement wherein the arms are generally straight and are arranged generally along the axis of the catheter tip section; the length of the basket assembly in its expanded arrangement being from about 20 mm to about 60 mm and the diameter of the basket assembly in its expanded arrangement being from about 10 mm to about 30 mm;
- 5 a control handle at the proximal end of the catheter body, said control handle having first and second movable members, each being movable between first and second positions;
- a first puller wire comprising a proximal end attached to the first movable member of the handle, and extending through the catheter body and into an off-axis lumen in the tip section, the distal end of the first puller wire being anchored to the tip section so that
- 10 movement of the first movable member from a first to a second position results in longitudinal movement of the first puller wire relative to the catheter body and deflection of the tip section.
- a second puller wire comprising a proximal end attached to the second movable member of the handle and extending through a lumen in the catheter body and a lumen of the tip section and the proximal fitting, the distal end of the second puller wire being attached to the distal fitting of the basket assembly such that movement of the second movable member from a first to a second position results in longitudinal movement of the second puller wire relative to the catheter body and expansion of the basket assembly; and
- 15 a plurality of electrode lead wires extending through the handle and catheter body, each lead wire attached to a corresponding electrode of the basket assembly.
- 20

54. The catheter of claim 53 wherein the length of the basket assembly in its expanded arrangement is from about 20 to about 30 mm.

- 25 55. The catheter of claim 53 wherein the diameter of the basket assembly in its expanded arrangement is from about 10 to about 30 mm.

56. The catheter of claim 53 wherein each arm of the basket assembly comprises a metal backbone, at least a portion of which forms an electrode.
- 30

57. The catheter of claim 56 wherein the metal backbone of each arm comprises an insulating coating covering at least a portion of the metal backbone.

58. The catheter of claim 57 wherein a middle portion of the metal backbone of each arm is exposed and forms an electrode.
- 35

59. The catheter of claim 58 wherein each arm comprises an electrode distal to the exposed portion of the metal backbone.

1           60. The catheter of claim 58 wherein each arm comprises an electrode proximal to  
the exposed portion of the metal backbone.

5           61. The catheter of claim 58 wherein each arm comprises electrodes proximal and  
distal to the exposed portion of the metal backbone.

10

15

20

25

30

35









Fig. 1



3/11

*Fig. 3*

*Fig. 4*





6/11




Fig. 6

7/11




Fig. 8A




Fig. 8B







Fig. 8

9/11





11/11




Fig. 11

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/13719

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :A61N 1/05

US CL :607/9

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 600/374, 375, 381; 607/9, 14, 98, 99, 101, 113, 122, 126

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,411,531 A (HILL et al.) 02 May 1995, entire document.	1-7, 13-21, 28
A	US 5,466,245 A (SPINELLI et al.) 14 November 1995, entire document.	1-61
A	US 5,700,282 A (ZABARA) 23 December 1997, entire document.	1-61
A, P	US 5,876,336 A (SWANSON et al.) 02 March 1999, entire document.	8-12, 22, 29-31, 41-47, 49-61

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

12 SEPTEMBER 1999

Date of mailing of the international search report

21 OCT 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

KENNEDY SCHAETZLE

Telephone No. (703) 308-2211